{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:28:36Z","timestamp":1793050116287,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","award":["MH31593"],"award-info":[{"award-number":["MH31593"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","award":["MH40856"],"award-info":[{"award-number":["MH40856"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","award":["MH19113"],"award-info":[{"award-number":["MH19113"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","award":["MHCRC43271"],"award-info":[{"award-number":["MHCRC43271"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.biopsych.2009.08.040","type":"journal-article","created":{"date-parts":[[2009,11,8]],"date-time":"2009-11-08T09:07:00Z","timestamp":1257671220000},"page":"255-262","source":"Crossref","is-referenced-by-count":861,"title":["Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs"],"prefix":"10.1016","volume":"67","author":[{"given":"Nancy C.","family":"Andreasen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peg","family":"Nopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Del","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beng-Choon","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2009.08.040_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archpsyc.1992.01820080023004","article-title":"The comprehensive assessment of symptoms and history (CASH)","volume":"49","author":"Andreasen","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0920-9964(95)95492-R","article-title":"The concept of dose years: A reliable method for calculating lifetime psychotropic drug exposure","volume":"15","author":"Miller","year":"1995","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2009.08.040_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-3956(74)90071-5","article-title":"Dose equivalence of the antipsychotic drugs","volume":"11","author":"Davis","year":"1974","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2009.08.040_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"suppl 12","key":"10.1016\/j.biopsych.2009.08.040_bib5","first-page":"5","article-title":"The expert consensus guideline series","volume":"64","author":"Kane","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"suppl 12","key":"10.1016\/j.biopsych.2009.08.040_bib6","first-page":"2","article-title":"The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders","volume":"64","author":"Kane","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2009.08.040_bib8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1176\/ajp.156.8.1200","article-title":"Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics","volume":"156","author":"Corson","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2009.08.040_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2009.08.040_bib11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia","volume":"54","author":"Small","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs","volume":"45","author":"Farde","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib16","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1176\/appi.ajp.161.9.1620","article-title":"Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: Differentiation from other atypical antipsychotics","volume":"161","author":"Tauscher","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2009.08.040_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/00023210-200115090-00001","article-title":"Choosing the right dose of antipsychotics in schizophrenia: Lessons from neuroimaging studies","volume":"15","author":"Tauscher","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2009.08.040_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1176\/foc.2.1.48","article-title":"Atypical antipsychotics: Mechanism of action","volume":"2","author":"Seeman","year":"2004","journal-title":"Focus"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322309011251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322309011251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T13:09:48Z","timestamp":1685192988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322309011251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0006322309011251"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2009.08.040","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}